Spike Protein News and Research

RSS

Structure of the SARS-CoV-2 spike protein provides clues to its evolution

Researchers at the Francis Crick Institute have characterized the structure of the SARS-CoV-2 spike protein as well as its most similar relative in a bat coronavirus. The structures provide clues about how the spike evolved and could help inform vaccine design.

9 Jul 2020

Tracing adaptation to ACE2 use in sarbecoviruses

A detailed study published on the preprint server bioRxiv in July 2020 argues that recombination accounts for the appearance of the ability of both SARS-CoV and SARS-CoV-2 to use the human angiotensin-converting enzyme (hACE) 2 as the binding receptor mediating viral infection of human cells.

8 Jul 2020

Research sheds doubt on the Pangolin link to SARS-CoV-2

A startling new study by researchers at the Broad Institute of MIT and the University of British Columbia and published on the preprint server bioRxiv* in July 2020 casts doubt on the hypothesis that the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was transmitted from pangolins acting as the intermediate host. Instead, the authors suggest, the pangolins themselves were incidentally infected from other animals in captivity or from humans.

8 Jul 2020

A biomaterial vaccine for SARS-CoV-2 - quick and scalable

A recent 'tour-de-force' research endeavor, led by scientists from Harvard University, explored the propensity of a biomaterial vaccine based on mesoporous silica rods to spawn highly protective humoral responses against relevant antigens of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2020

Study suggests natural UV radiation protects against coronavirus

A new study by scientists at the University of Edinburgh and published on the preprint server medRxiv* in July 2020 suggests an interesting link between ultraviolet A radiation and deaths due to COVID-19. While this is an observational study, which means that direct inferences cannot be drawn from this finding, it does, however, suggest better strategies for reducing the death rate due to COVID-19.

8 Jul 2020

Study of glycosylation on SARS-CoV-2 spike protein

The first intimation of the current COVID-19 crisis came with the news of severe pneumonic illness caused by an unknown agent in a Chinese city called Wuhan, issued on the last day of 2019. Following this, researchers found the cause to be a novel coronavirus, closely related to the earlier SARS virus, now called severe acute respiratory syndrome coronavirus 2.

8 Jul 2020

Gene expression networks flag potential therapeutic targets for SARS-CoV-2

An international team of researchers from Canada, Australia, the Netherlands, and the United States has identified dozens of genes that could contribute to the pathology of coronavirus disease 2019 (COVID-19) and serve as potential therapeutic targets.

7 Jul 2020

Evolutionary snapshot reveals genetic stability of SARS-CoV-2

A multinational study currently available on the bioRxiv preprint server shows that in the early large genome of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) only a handful of amino acids are exchanged, implying a relatively low mutation rate and selection pressure.

7 Jul 2020

Spike proteins of SARS-CoV-2 covered by mobile glycans that shield its surface

A new study of the structural dynamics of the SARS-CoV-2 spike protein published in the preprint server bioRxiv in July 2020 reports on the epitopes that could be possible immune targets for the development of vaccines.

7 Jul 2020

SARS-CoV-2 spike protein hidden as pH changes

Now, a new study published on the preprint server bioRxiv in July 2020 reports the role of pH in helping the virus escape neutralization by antibodies, by inducing a key conformational switch.

7 Jul 2020

Human trials of potential COVID-19 vaccine commence in South Australia

A potential COVID-19 vaccine developed at Flinders University has commenced human trials in South Australia.

6 Jul 2020

Oxford COVID-19 vaccine trials move to stage 3 human trials

The technical name of the vaccine is ChAdOx1 nCoV-19 (AZD1222), as it is made from a virus called ChAdOx1, which is a weakened and non-replicating version of a common cold virus (adenovirus). The vaccine has been engineered to express the SARS-CoV-2 spike protein.

5 Jul 2020

Mutated European strain of coronavirus more contagious but less potent

The coronavirus pandemic is far from over as it actively spreads across the globe. The infection toll has reached a staggering 10.84 million people since it emerged in late December 2019 in Wuhan City, China. The virus that has left the city has now spread to 188 countries and territories and has mutated, becoming more infectious.

3 Jul 2020

Pfizer/BioNTech COVID-19 vaccine shows promise - virus neutralizing antibodies achieved

In a recent medRxiv* paper, a research group from the U.S. and Germany showed a robust immunogenic response and a promising safety profile of the novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) – actively encouraging its accelerated clinical development and potential rapid production.

2 Jul 2020

Novavax SARS-CoV-2 vaccine candidate shows promise in animal models

A new study published on the preprint server bioRxiv in June 2020 shows that a candidate spike protein vaccine can induce neutralizing antibodies, antiviral T cell responses, and protection against infection.

2 Jul 2020

Blood cell damage in COVID-19 may compromise oxygen transport

Researchers in the U.S. have shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may alter key protein structures on red blood cells and compromise the transport and delivery of oxygen in patients with coronavirus disease 2019 (COVID-19).

1 Jul 2020

Striking CryoEM image of SARS-CoV-2

A new study by researchers from the UK and Germany and published on the preprint server bioRxiv in June 2020 reports the results of a detailed study of the S protein on the intact virus, using cryoelectron microscopy (cryoEM) and tomography. This could help understand the conformation of the S protein on the virion and how it interacts with neutralizing antibodies.

30 Jun 2020

New approach holds incredible potential for developing new therapeutics

Nearly every drug that is, or has ever been, used was derived from nature -- harnessing compounds created by organisms over eons to fight diseases. But decades ago, biochemists postulated that it might be possible to design a new drug from scratch by linking up amino acids in precise ways.

30 Jun 2020

Salk Institute expands research to find treatments and cures for COVID-19

As the COVID-19 pandemic continues across the globe, the Salk Institute joins in efforts to understand the fundamental science behind the novel coronavirus to pave the way to treatments and cures.

30 Jun 2020

Spike protein and human ACE2 binding ability shows SARS-CoV-2 viral adaptation

A new study published on the preprint server bioRxiv in June 2020 reports some important findings that could shed light on this question. As the pandemic marches on, having claimed over 500,000 lives and caused well over 10 million infections to date, the task of defining and predicting factors that predispose to infectivity across species becomes ever more critical.

30 Jun 2020